Stock Market Reviews

Read and share opinions on SILO (Silo Pharma, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
  Oct 1, 2025
• Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
  Sep 29, 2025
• Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
  Sep 23, 2025
• EXCLUSIVE: Silo Pharma Partners With Fireblocks To Advance Crypto Treasury Strategy Acquisition And Security
  Sep 23, 2025
• Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
  Sep 9, 2025
• Silo Pharma Second Quarter 2025 Earnings: US$0.19 loss per share (vs US$0.30 loss in 2Q 2024)
  Aug 15, 2025
• Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
  Jul 16, 2025
• Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
  Jul 7, 2025
• Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
  Jun 27, 2025
• Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
  Jun 25, 2025
• Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
  Jun 25, 2025
• Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
  Jun 11, 2025
• Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
  May 21, 2025
• Silo Pharma Announces Closing of $2 Million Public Offering
  May 16, 2025
• Silo Pharma Announces Pricing of $2 Million Public Offering
  May 15, 2025
• Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
  May 14, 2025
• Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
  May 14, 2025
• Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
  Apr 30, 2025